Difficult decisions in the intensive care unit: An illustrative case

Anaesthesia and Intensive Care

Volumn 35, Issue 5, 2007, Pages 748-759

  Freshwater Turner, D A ^a,b   Boots, R J ^a,b   Bowman, R N ^a,b   Healy, H G ^a,b   Klestov, A C ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Clinical decision making; Renal failure; Small intestine; Subarachnoid haemorrhage; Wegener's granulomatosis

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

ADOLESCENT; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DECISION MAKING; EVIDENCE BASED MEDICINE; HUMAN; INTENSIVE CARE UNIT; LUNG HEMORRHAGE; LUNG INFILTRATE; MALE; PATIENT CARE; PNEUMOCYSTIS PNEUMONIA; THORAX RADIOGRAPHY; WEGENER GRANULOMATOSIS;

EID: 35348831256     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0703500515     Document Type: Article

References (68)

1. Glazebrook RM, Harrison SL. Obstacles and solutions to maintenance of advanced procedural skills for rural and remote medical practitioners in Australia. Rural Remote Health 2006; 6:502.
2. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. An evaluation of outcome from intensive care in major medical centers. Ann Intern Med 1986; 104:410-418.
3. Richardson WS. We should overcome the barriers to evidence-based clinical diagnosis! J Clin Epidemiol 2007; 60:217-227.
4. Langford CA. Wegener's granulomatosis: current and upcoming therapies. Arthritis Res Ther 2003; 5:180-191.
5. White E, Lynch J. Pharmacological therapy for Wegener's Granulomatosis. Drugs 2006; 66:1209-1228.
6. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85.
7. de Groot K, Adu D, Savage CO. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16:2018-2027.
8. Winters JL, Pineda AA. New directions in plasma exchange. Curr Opin Hematol 2003; 10:424-428.
9. Gaskin G, Pusey CD. Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther Apher 2001; 5:176-181.
10. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42:1149-1153.
11. Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial 2005; 9:391-395.
12. Ferraro AJ, Day CJ, Drayson MT, Savage CO. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005; 20:622-625.
13. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257:540-548.
14. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-187.
15. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-858.
16. Samuels J, Spiera R. Newer therapeutic approaches to the vasculitides: biologic agents. Rheum Dis Clin North Am 2006; 32:187-200, xi.
17. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352:330-332.
18. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44:1149-1154.
19. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-1132.
20. Anonymous. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
21. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, Savage C et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721.
22. Hogg K, Ashton A. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Antithrombotic treatment of below knee deep venous thrombosis. Emerg Med J 2003; 20:364-365.
23. Leon L, Giannoukas AD, Dodd D, Chan P, Labropoulos N. Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg 2005; 29:10-17.
24. Gainza FJ, Minguela I, Lopez-Vidaur I, Ruiz LM, Lampreabe I. Evaluation of complications due to percutaneous renal biopsy in allografts and native kidneys with color-coded Doppler sonography. Clin Nephrol 1995; 43:303-308.
25. Whittier WL, Korbet SM. Renal biopsy: update. Curr Opin Nephrol Hypertens 2004; 13:661-665.
26. Mackie GC, Davies PF, Challis DR, Middleton IS. Renal infarction secondary to a subcapsular haematoma following percutaneous renal biopsy. Australas Radiol 2004; 48:207-210.
27. Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest 2002; 122:963-967.
28. Joels CS, Sing RF, Heniford BT. Complications of inferior vena cava filters. Am Surg 2003; 69:654-659.
29. Kirilcuk NN, Herget EJ, Dicker RA, Spain DA, Hellinger JC, Brundage SI. Are temporary inferior vena cava filters really temporary? Am J Surg 2005; 190:864-870.
30. West NJ. Prevention and treatment of hemorrhagic cystitis. Pharmacotherapy 1997; 17:696-706.
31. Rotterdam H, Tsang P. Gastrointestinal disease in the immunocompromised patient. Hum Pathol 1994; 25:1123-1140.
32. Storesund B, Gran JT, Koldingsnes W. Severe intestinal involvement in Wegener's granulomatosis: report of two cases and review of the literature. Br J Rheumatol 1998; 37:387-390.
33. Chow FY, Hooke D, Kerr PG. Severe intestinal involvement in Wegener's granulomatosis. J Gastroenterol Hepatol 2003; 18:749-750.
34. Izzedine H, Lacaille S, Deray G. An unusual presentation of relapsing Wegener's granulomatosis. Nephrol Dial Transplant 2001; 16:1511-1512.
35. Seror R, Mahr A, Ramanoelina J, Pagnoux C, Cohen P, Guillevin L. Central nervous system involvement in Wegener granulomatosis. Medicine (Baltimore) 2006; 85:54-65.
36. Takei H, Komaba Y, Kitamura H, Hayama N, Osawa H, Furukawa T et al. Aneurysmal subarachnoid hemorrhage in a patient with Wegener's granulomatosis. Clin Exp Nephrol 2004; 8:274-278.
37. Naval NS, Stevens RD, Mirski MA, Bhardwaj A. Controversies in the management of aneurysmal subarachnoid hemorrhage. Crit Care Med 2006; 34:511-524.
38. Al-Shahi R, White PM, Davenport RJ, Lindsay KW. Subarachnoid haemorrhage. BMJ 2006; 333:235-240.
39. Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005: CD000277.
40. Rinkel GJ, Feigin VL, Algra A, van Gijn J. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2004: CD000483.
41. MacDonald RL. Evidence-based treatment of subarachnoid hemorrhage: current status and future possibilities. Clin Neurosurg 2006; 53:257-266.
42. van der Schaaf I, Algra A, Wermer M, Molyneux A, Clarke M, van Gijn J et al. Endovascular coiling versus neurosurgical clipping for patients with aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005: CD003085.
43. Whitfield PC, Kirkpatrick PJ. Timing of surgery for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2001: CD001697.
44. Round A. Introduction to clinical reasoning. J Eval Clin Pract 2001; 7:109-117.
45. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312:71-72.
46. Tavakoli M, Davies HT, Thomson R. Decision analysis in evidence-based decision making. J Eval Clin Pract 2000; 6:111-120.
47. Croskerry P. Achieving quality in clinical decision making: cognitive strategies and detection of bias. Acad Emerg Med 2002; 9:1184-1204.
48. Croskerry P. The theory and practice of clinical decision-making. Can J Anesth 2005; 52:R1.
49. Redelmeier DA, Shafir E. Medical decision making in situations that offer multiple alternatives. JAMA 1995; 273:302-305.
50. Croskerry P. Cognitive forcing strategies in clinical decision-making. Ann Emerg Med 2003; 41:110-120.
51. Klein JG. Five pitfalls in decisions about diagnosis and prescribing. BMJ 2005; 330:781-783.
52. Ritov I, Baron J. Status-quo and omission biases. J Risk Uncertain 1992; 5:49-61.
53. Johnson EJ, Goldstein D. Medicine. Do defaults save lives? Science 2003; 302:1338-1339.
54. Shafir E, Simonson I, Tversky A. Reason-based choice. Cognition 1993; 49:11-36.
55. Spranca M, Minsk E, Baron J. Omission and comission in judgment and choice. J Exp Soc Psychol 1991; 27:76-105.
56. Ritov I, Baron J. Reluctance to vaccinate: omission bias and ambiguity. J Behav Dec Making 1990; 3:263-277.
57. Aberegg SK, Haponik EF, Terry PB. Omission bias and decision making in pulmonary and critical care medicine. Chest 2005; 128:1497-1505.
58. Redelmeier DA. The cognitive psychology of missed diagnoses. Ann Intern Med 2005; 142:115-120.
59. Poses RM, Anthony M. Availability, wishful thinking, and physicians' diagnostic judgments for patients with suspected bacteremia. Med Decis Making 1991; 11:159-168.
60. Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol 2005; 11:314-318.
61. Mahoney MJ. Publication prejudices: an experimental study of confirmatory bias in the peer review system. Cognit Ther Res 1977; 1:161-175.
62. Wallsten TS. Physician and medical student bias in evaluating diagnostic information. Med Decis Making 1981; 1:145-164.
63. McNeil BJ, Pauker SG, Sox HC Jr, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med 1982; 306:1259-1262.
64. Tymstra T. The imperative character of medical technology and the meaning of "anticipated decision regret". Int J Technol Assess Health Care 1989; 5:207-213.
65. Tubbs EP, Elrod JA, Flum DR. Risk taking and tolerance of uncertainty: implications for surgeons. J Surg Res 2006; 131:1-6.
66. Pronovost PJ, Holzmueller CG, Clattenburg L, Berenholtz S, Martinez EA, Paz JR et al. Team care: beyond open and closed intensive care units. Curr Opin Crit Care 2006; 12:604-608.
67. Pronovost PJ, Angus DC, Dorman T, Robinson KA, Dremsizov TT, Young TL. Physician staffing patterns and clinical outcomes in critically ill patients: a systematic review. JAMA 2002; 288:2151-2162.
68. Fuchs RJ, Berenholtz SM, Dorman T. Do intensivists in ICU improve outcome? Best Pract Res Clin Anaesthesiol 2005; 19:125-135.